USA flag logo/image

An Official Website of the United States Government

MAMMALIAN HEPATOCYTES, A SOURCE OF THERAPEUTIC PROTEINS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61038
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
GM066480
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MULTICELL TECHNOLOGIES, INC.
MULTICELL TECHNOLOGIES, INC. 701 GEORGE WASHIGNTON HIGHWAY LINCOLN, RI 02865
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: MAMMALIAN HEPATOCYTES, A SOURCE OF THERAPEUTIC PROTEINS
Agency: HHS
Contract: 1R43GM066480-01
Award Amount: $133,586.00
 

Abstract:

DESCRIPTION (provided by applicant): The safe and efficient production of novel therapeutic proteins represents an expanding market of the biopharmaceutical industry that is fueled by the recent completion of the Human Genome Project and by rapid technological advances in the field of proteomics. Although many of these therapeutic proteins will be mass-produced by recombinant technology, there will be occasions where the commercialization of complex heterologous proteins that require extensive posttranslational modification will be better accomplished by isolating the native form of the protein. MultiCell Technologies (MCT) has developed proprietary technology for the long-term cultivation of primary human hepatocytes, as well as created numerous immortalized mammalian hepatocyte cell lines, that may provide a readily available and reproducible source of therapeutic plasma proteins (TPP). The production of TPP by cell-based systems would avoid the hazards of blood-derived products, the most notable of which is viral contamination. Since many plasma proteins require liver specific posttranslational modifications for full activity, we reason that hepatocyte-derived TPP may out perform their recombinant counterpart. In this Phase I application, we plan to investigate the feasibility of utilizing mammalian hepatocytes as a commercial source of therapeutic plasma proteins. Our rationale is founded on the development of several proprietary technologies that has led to the creation of two strategies for hepatocyte-based protein expression systems. In Aim 1 we plan to explore the utilization of primary human hepatocyte cultures for the production of TPP. The feasibility of this strategy is based upon MCT's development of proprietary serum-free culture conditions that support the long-term survival and function of primary and cryopreserved human hepatocytes. In Aim 2 we propose to evaluate the biological activity of hepatocyte-derived plasma proteins in order to confirm that immortalized hepatocyte cell lines can be used as a source of functional plasma proteins.

Principal Investigator:

Ronald A. Faris
4017387560
FARIS@MULTICELLTECHNOLOGIES.COM

Business Contact:


4017387560
TRENKLER@MULTICELLTECHNOLOGIES.COM
Small Business Information at Submission:

MULTICELL ASSOCIATES, INC.
MULTICELL ASSOCIATES 55 ACCESS RD, STE 700 WARWICK, RI 02886

EIN/Tax ID: 050483322
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No